出版：MarketsandMarkets（マーケッツアンドマーケッツ） 出版年月：2023年7月
糖化アルブミン測定市場 : 用途 (前糖尿病、1 型糖尿病、2 型糖尿病)、エンドユーザー (病院＆糖尿病ケアセンター、診断研究所)、地域 (北米、ヨーロッパ、APAC、ラテンアメリカ、MENA) – 2028年までの世界予測
Glycated Albumin Assay Market by Application (Prediabetes, Type 1 Diabetes, Type 2 Diabetes), End User (Hospitals & Diabetic Care Center, Diagnostic Laboratory) & Region (North America, Europe, APAC, Latin America, & MENA) – Global Forecast to 2028
| ページ数 | 124 |
| 図表数 | 103 |
| 種別 | 英文調査報告書 |
| 価格 |
The global glycated albumin assay market is projected to reach USD 0.3 billion by 2028 from USD 0.2 billion in 2023, at a CAGR of 8.9% during the forecast period. Market growth is driven by factors such as the increased number of diabetic patients above the age of 65 years and government initiatives for disease diagnosis. On the other hand, challenges associated with the glycated albumin assay market, like unfavorable reimbursement scenarios, are the major factors restricting market growth.
“The prediabetic segment accounted for the highest growth rate in the glycated albumin assay market, by application, during the forecast period”
The glycated albumin assay market is segmented into prediabetes, type 1 diabetes, and type 2 diabetes. In 2022, the prediabetes segment accounted for the highest glycated albumin assay market growth rate. The increasing focus on the prevention of lifestyle diseases like diabetes, growth in the number of diagnostic laboratories, and improving healthcare infrastructure in emerging countries are major factors contributing to this segment’s growth.
“The diagnostic laboratories segment accounted for the highest growth in the glycated albumin assay market, by end-user, during the forecast period”
The glycated albumin assay market is segmented into hospitals and diabetes care centers, diagnostic laboratories, and other end-user based on end users. In 2022, the diagnostic laboratories segment accounted for the highest glycated albumin assay market growth rate. Diagnostics laboratories often offer cost-effective and convenient testing options for healthcare providers and patients. By outsourcing glycated albumin testing to diagnostics laboratories, healthcare providers can avoid the need for in-house testing facilities and associated costs. Additionally, patients can visit diagnostics laboratories for their glycated albumin assays without the need for hospitalization or specialized clinic visits. The cost-effectiveness and convenience of diagnostics laboratories make them an attractive option, leading to increased demand and segment growth.
“Asia Pacific: The fastest-growing region in glycated albumin assay market”
The North American, European, Asia Pacific, Latin American, Middle Eastern, and African regions make up the major segments of the worldwide glycated albumin assay market. The highest CAGR is anticipated to be recorded over the forecast period in the Asia Pacific region. The glycated albumin assay market in this region is expanding as a result of an increase in diabetes awareness programmes and favourable government healthcare policies.
The primary interviews conducted for this report can be categorized as follows:
• By Company Type: Tier 1 – 40%, Tier 2 – 30%, and Tier 3 – 30%
• By Designation: C-level – 27%, D-level – 18%, and Others – 55%
• By Region: North America – 51%, Europe – 21%, Asia Pacific – 18%, Latin America – 6% , and the Middle East & Africa – 4%
List of Companies Profiled in the Report:
• Asahi Kasei Corporation (Japan)
• Beijing Strong Biotechnologies, Inc. (China)
• Diazyme Laboratories, Inc. (US)
• DxGen Corp. (South Korea)
• Weldon Biotech, Inc.(India)
• Hzymes Biotech (China)
Research Coverage:
This report provides a detailed picture of the global glycated albumin assay market. It aims at estimating the size and future growth potential of the market across different segments, such as application, end user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profile and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall glycated albumin assay market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
目次
1 INTRODUCTION 19
1.1 STUDY OBJECTIVES 19
1.2 MARKET DEFINITION 19
1.2.1 INCLUSIONS AND EXCLUSIONS 20
1.3 MARKET SCOPE 20
1.3.1 MARKET SEGMENTATION 20
1.3.2 GEOGRAPHICAL SCOPE 20
1.3.3 YEARS CONSIDERED 21
1.4 CURRENCY CONSIDERED 21
1.5 LIMITATIONS 21
1.6 STAKEHOLDERS 22
1.7 RECESSION IMPACT 22
2 RESEARCH METHODOLOGY 23
2.1 RESEARCH DATA 23
2.2 RESEARCH APPROACH 23
FIGURE 1 GLYCATED ALBUMIN ASSAY MARKET: RESEARCH DESIGN METHODOLOGY 23
2.2.1 SECONDARY DATA 24
2.2.1.1 Key data from secondary sources 24
2.2.2 PRIMARY DATA 25
2.2.2.1 Primary sources 26
2.2.2.2 Key data from primary sources 27
2.2.2.3 Key industry insights 27
2.2.2.4 Breakdown of primary interviews 28
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 28
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 28
2.3 MARKET SIZE ESTIMATION 29
2.3.1 BOTTOM-UP APPROACH 29
2.3.1.1 Approach 1: Company revenue estimation approach 30
FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH 30
2.3.1.2 Approach 2: Primary interviews 30
2.3.1.3 Growth forecast 30
2.3.1.4 Glycated Albumin Assay Market: CAGR Projections 31
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 31
2.3.2 TOP-DOWN APPROACH 31
FIGURE 6 GLYCATED ALBUMIN ASSAY MARKET: TOP-DOWN APPROACH 31
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION METHODOLOGY 33
FIGURE 7 DATA TRIANGULATION METHODOLOGY 33
2.5 MARKET SHARE ANALYSIS 33
2.6 STUDY ASSUMPTIONS 34
2.7 STUDY LIMITATIONS 34
2.8 GROWTH RATE ASSUMPTIONS 35
2.9 RISK ASSESSMENT 35
2.9.1 GLYCATED ALBUMIN ASSAY MARKET: RISK ASSESSMENT ANALYSIS 35
2.10 RECESSION IMPACT ANALYSIS 35
3 EXECUTIVE SUMMARY 37
FIGURE 8 GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 37
FIGURE 9 GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 38
FIGURE 10 GLYCATED ALBUMIN ASSAY MARKET, BY REGION, 2023 VS. 2028 (USD MILLION) 39
4 PREMIUM INSIGHTS 40
4.1 GLYCATED ALBUMIN ASSAY MARKET OVERVIEW 40
FIGURE 11 INCREASING PREVALENCE OF DIABETES TO DRIVE MARKET 40
4.2 GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2023 VS. 2028 41
FIGURE 12 TYPE 2 DIABETES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 41
4.3 GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2023 VS. 2028 41
FIGURE 13 HOSPITALS AND DIABETIC CARE CENTERS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 41
4.4 GLYCATED ALBUMIN ASSAY MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES 42
FIGURE 14 ASIA PACIFIC TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 42
5 MARKET OVERVIEW 43
5.1 INTRODUCTION 43
5.2 MARKET DYNAMICS 43
FIGURE 15 GLYCATED ALBUMIN ASSAY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 43
5.2.1 DRIVERS 44
5.2.1.1 Rising incidence of diabetes 44
FIGURE 16 PREVALENCE OF DIABETES IN ADULTS (20–79 YEARS), BY REGION, 2021 VS. 2045 (USD MILLION) 45
TABLE 1 TOTAL HEALTH EXPENDITURE (USD) FOR DIABETES (20–79 YEARS), BY COUNTRY (2021) 45
5.2.1.2 Growing focus on early detection of diabetes 45
5.2.1.3 Increase in age-associated diabetic ailments 46
5.2.2 RESTRAINTS 47
5.2.2.1 Unfavorable reimbursement scenario 47
5.2.3 OPPORTUNITIES 47
5.2.3.1 Rising investments in life sciences research 47
5.2.4 CHALLENGES 48
5.2.4.1 Stringent regulatory requirements for diagnostic products 48
5.2.4.2 Presence of alternative tests 48
5.3 PRICING ANALYSIS 49
TABLE 2 AVERAGE SELLING PRICE OF GLYCATED ALBUMIN ASSAY PRODUCTS 49
5.4 PATENT ANALYSIS 50
FIGURE 17 PATENT ANALYSIS FOR GLYCATED ALBUMIN ASSAYS (JANUARY 2013–DECEMBER 2022) 50
5.4.1 GLYCATED ALBUMIN ASSAY MARKET: LIST OF MAJOR PATENTS 51
5.5 VALUE CHAIN ANALYSIS 52
FIGURE 18 GLYCATED ALBUMIN ASSAY MARKET: MAJOR VALUE IS ADDED DURING MANUFACTURING & ASSEMBLY PHASES 52
5.6 SUPPLY CHAIN ANALYSIS 53
FIGURE 19 GLYCATED ALBUMIN ASSAY MARKET: SUPPLY CHAIN ANALYSIS 54
5.7 ECOSYSTEM ANALYSIS 54
FIGURE 20 GLYCATED ALBUMIN ASSAY MARKET: ECOSYSTEM MAP 55
5.7.1 GLYCATED ALBUMIN ASSAY MARKET: ECOSYSTEM ROLE 55
5.8 PORTER’S FIVE FORCES ANALYSIS 55
TABLE 3 GLYCATED ALBUMIN ASSAY MARKET: PORTER’S FIVE FORCES ANALYSIS 56
5.8.1 THREAT OF NEW ENTRANTS 56
5.8.2 THREAT OF SUBSTITUTES 56
5.8.3 BARGAINING POWER OF BUYERS 56
5.8.4 BARGAINING POWER OF SUPPLIERS 56
5.8.5 INTENSITY OF COMPETITIVE RIVALRY 57
5.9 REGULATORY LANDSCAPE 57
TABLE 4 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 57
TABLE 5 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 57
TABLE 6 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 58
TABLE 7 MIDDLE EAST: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 58
5.9.1 NORTH AMERICA 58
5.9.1.1 US 58
5.9.1.2 Canada 58
5.9.2 EUROPE 59
TABLE 8 EUROPE: CLASSIFICATION OF DEVICES 59
5.9.3 ASIA PACIFIC 60
5.9.3.1 China 60
5.9.3.2 Japan 60
5.9.3.3 India 60
5.9.4 LATIN AMERICA 60
5.9.4.1 Brazil 61
5.9.4.2 Mexico 61
5.9.5 MIDDLE EAST 61
5.9.6 AFRICA 61
5.10 TRADE ANALYSIS 62
5.10.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS 62
5.10.1.1 Import data for diagnostic and laboratory reagents, by country, 2018–2022 (USD million) 62
5.10.1.2 Export data for diagnostic and laboratory reagents, by country, 2018–2022 (USD million) 62
5.11 TECHNOLOGY ANALYSIS 62
5.12 KEY CONFERENCES AND EVENTS 63
TABLE 9 DETAILED LIST OF CONFERENCES AND EVENTS (2022−2023) 63
5.13 PESTLE ANALYSIS 64
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 65
FIGURE 21 GLYCATED ALBUMIN ASSAY MARKET: REVENUE SHIFT MAPPING 65
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA 66
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS 66
FIGURE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR GLYCATED ALBUMIN ASSAYS 66
TABLE 10 GLYCATED ALBUMIN ASSAY MARKET: INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS (%) 66
5.15.2 BUYING CRITERIA 66
FIGURE 23 GLYCATED ALBUMIN ASSAY MARKET: KEY BUYING CRITERIA 66
TABLE 11 KEY BUYING CRITERIA FOR GLYCATED ALBUMIN ASSAYS, BY END USER 67
5.16 CASE STUDY ANALYSIS 67
FIGURE 24 CASE STUDY ANALYSIS: MARKET ASSESSMENT AND CONSUMER BUYING BEHAVIOR IN INDIA 67
6 GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION 68
6.1 INTRODUCTION 69
TABLE 12 GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 69
6.2 TYPE 2 DIABETES 69
6.2.1 DIETARY AND LIFESTYLE CHANGES TO CONTRIBUTE TO MARKET GROWTH 69
TABLE 13 GLYCATED ALBUMIN ASSAY MARKET FOR TYPE 2 DIABETES, BY REGION, 2021–2028 (USD MILLION) 70
6.3 PREDIABETES 71
6.3.1 INSULIN RESISTANCE AND RISING CASES OF PREDIABETES TO DRIVE MARKET 71
TABLE 14 GLYCATED ALBUMIN ASSAY MARKET FOR PREDIABETES, BY REGION, 2021–2028 (USD MILLION) 71
6.4 TYPE 1 DIABETES 72
6.4.1 INCREASING INCIDENCE AMONG CHILDREN AND ADOLESCENTS TO SUPPORT MARKET GROWTH 72
TABLE 15 INCIDENCE OF TYPE 1 DIABETES IN CHILDREN AND ADOLESCENTS AGED 0 TO 19, BY REGION, 2021 (THOUSANDS) 72
TABLE 16 GLYCATED ALBUMIN ASSAY MARKET FOR TYPE 1 DIABETES, BY REGION, 2021–2028 (USD MILLION) 73
7 GLYCATED ALBUMIN ASSAY MARKET, BY END USER 74
7.1 INTRODUCTION 75
TABLE 17 GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 75
7.2 HOSPITALS AND DIABETES CARE CENTERS 75
7.2.1 ABILITY TO OFFER RAPID RESULTS IN ACCESSIBLE SETTING TO DRIVE MARKET 75
TABLE 18 GLYCATED ALBUMIN ASSAY MARKET FOR HOSPITALS AND DIABETES CARE CENTERS, BY REGION, 2021–2028 (USD MILLION) 76
7.3 DIAGNOSTIC LABORATORIES 77
7.3.1 RISING OUTSOURCING OF RESEARCH ACTIVITIES FOR COST REDUCTION TO DRIVE MARKET 77
TABLE 19 GLYCATED ALBUMIN ASSAY MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2021–2028 (USD MILLION) 77
7.4 OTHER END USERS 78
TABLE 20 GLYCATED ALBUMIN ASSAY MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION) 78
8 GLYCATED ALBUMIN ASSAY MARKET, BY REGION 79
8.1 INTRODUCTION 80
TABLE 21 GLYCATED ALBUMIN ASSAY MARKET, BY REGION, 2021–2028 (USD MILLION) 80
8.2 NORTH AMERICA 80
FIGURE 25 NORTH AMERICA: GLYCATED ALBUMIN ASSAY MARKET SNAPSHOT 81
TABLE 22 NORTH AMERICA: GLYCATED ALBUMIN ASSAY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 82
TABLE 23 NORTH AMERICA: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 82
TABLE 24 NORTH AMERICA: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 82
8.2.1 US 83
8.2.1.1 High healthcare expenditure for diabetes treatment & diagnosis to drive market 83
TABLE 25 US: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 83
TABLE 26 US: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 84
8.2.2 CANADA 84
8.2.2.1 Rising awareness of early diabetes detection to support market growth 84
TABLE 27 INCIDENCE OF DIABETES IN CANADA, 2019 VS. 2029 84
TABLE 28 CANADA: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 85
TABLE 29 CANADA: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 85
8.2.3 NORTH AMERICA: RECESSION IMPACT 86
8.3 EUROPE 86
TABLE 30 PREVALENCE OF DIABETES IN EUROPE, 2021 VS. 2045 86
TABLE 31 EUROPE: GLYCATED ALBUMIN ASSAY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 87
TABLE 32 EUROPE: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 87
TABLE 33 EUROPE: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 87
8.3.1 GERMANY 88
8.3.1.1 Provision of healthcare coverage for technologically advanced assays to drive market 88
TABLE 34 GERMANY: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 88
TABLE 35 GERMANY: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 89
8.3.2 UK 89
8.3.2.1 Rising geriatric population and diabetes-associated ailments to drive market 89
TABLE 36 UK: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 90
TABLE 37 UK: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 90
8.3.3 FRANCE 90
8.3.3.1 Increasing R&D expenditure for product commercialization to drive market 90
TABLE 38 FRANCE: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 91
TABLE 39 FRANCE: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 91
8.3.4 ITALY 92
8.3.4.1 Improvements in healthcare infrastructure to support market growth 92
TABLE 40 ITALY: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 92
TABLE 41 ITALY: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 92
8.3.5 SPAIN 93
8.3.5.1 Rising incidence of diabetes among senior women to support market growth 93
TABLE 42 SPAIN: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 93
TABLE 43 SPAIN: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 93
8.3.6 REST OF EUROPE 94
TABLE 44 REST OF EUROPE: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 94
TABLE 45 REST OF EUROPE: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 95
8.3.7 EUROPE: RECESSION IMPACT 95
8.4 ASIA PACIFIC 95
FIGURE 26 ASIA PACIFIC: GLYCATED ALBUMIN ASSAY MARKET SNAPSHOT 96
TABLE 46 ASIA PACIFIC: GLYCATED ALBUMIN ASSAY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 97
TABLE 47 ASIA PACIFIC: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 97
TABLE 48 ASIA PACIFIC: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 97
8.4.1 CHINA 98
8.4.1.1 Improving healthcare infrastructure to propel market 98
TABLE 49 CHINA: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 98
TABLE 50 CHINA: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 99
8.4.2 JAPAN 99
8.4.2.1 Universal healthcare reimbursement policy to support market growth 99
TABLE 51 JAPAN: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 100
TABLE 52 JAPAN: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 100
8.4.3 INDIA 100
8.4.3.1 implementation of favorable government initiatives to drive market 100
TABLE 53 INDIA: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 101
TABLE 54 INDIA: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 101
8.4.4 REST OF ASIA PACIFIC 101
TABLE 55 REST OF ASIA PACIFIC: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 102
TABLE 56 REST OF ASIA PACIFIC: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 102
8.4.5 ASIA PACIFIC: RECESSION IMPACT 102
8.5 LATIN AMERICA 103
8.5.1 RISING GOVERNMENT-FUNDED PROGRAMS FOR ACCURATE AND EARLY DISEASE DIAGNOSIS TO DRIVE MARKET 103
TABLE 57 LATIN AMERICA: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 103
TABLE 58 LATIN AMERICA: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 104
8.5.2 LATIN AMERICA: RECESSION IMPACT 104
8.6 MIDDLE EAST & AFRICA 104
8.6.1 EXPANSION OF KEY MARKET PLAYERS TO SUPPORT MARKET GROWTH 104
TABLE 59 MIDDLE EAST & AFRICA: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 105
TABLE 60 MIDDLE EAST & AFRICA: GLYCATED ALBUMIN ASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 105
8.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 105
9 COMPETITIVE LANDSCAPE 106
9.1 OVERVIEW 106
9.2 REVENUE SHARE ANALYSIS OF LEADING MARKET PLAYERS 106
FIGURE 27 GLYCATED ALBUMIN ASSAY MARKET: REVENUE SHARE ANALYSIS 106
9.3 MARKET SHARE ANALYSIS 107
9.3.1 GLYCATED ALBUMIN ASSAY MARKET 107
FIGURE 28 GLYCATED ALBUMIN ASSAY MARKET SHARE, BY KEY PLAYER (2022) 107
TABLE 61 GLYCATED ALBUMIN ASSAY MARKET: INTENSITY OF COMPETITIVE RIVALRY 107
9.4 GLYCATED ALBUMIN ASSAY MARKET: COMPANY EVALUATION MATRIX 108
9.4.1 STARS 108
9.4.2 EMERGING LEADERS 108
9.4.3 PERVASIVE PLAYERS 108
9.4.4 PARTICIPANTS 109
FIGURE 29 GLYCATED ALBUMIN ASSAY MARKET: COMPANY EVALUATION MATRIX (2022) 109
9.5 GLYCATED ALBUMIN ASSAY MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022) 109
9.5.1 PROGRESSIVE COMPANIES 109
9.5.2 STARTING BLOCKS 110
9.5.3 RESPONSIVE COMPANIES 110
9.5.4 DYNAMIC COMPANIES 110
FIGURE 30 GLYCATED ALBUMIN ASSAY MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022) 110
9.6 COMPETITIVE BENCHMARKING 111
9.6.1 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS 111
FIGURE 31 GLYCATED ALBUMIN ASSAY MARKET: PRODUCT AND REGIONAL FOOTPRINT ANALYSIS 111
TABLE 62 GLYCATED ALBUMIN ASSAY MARKET: COMPETITIVE EVALUATION OF KEY PLAYERS 111
TABLE 63 GLYCATED ALBUMIN ASSAY MARKET: COMPANY PRODUCT FOOTPRINT 111
TABLE 64 GLYCATED ALBUMIN ASSAY MARKET: COMPANY REGIONAL FOOTPRINT 112
10 COMPANY PROFILES 113
(Business overview, Products offered, Recent Developments, MNM view)*
10.1 KEY PLAYERS 113
10.1.1 ASAHI KASEI CORPORATION 113
TABLE 65 ASAHI KASEI CORPORATION: BUSINESS OVERVIEW 113
FIGURE 32 ASAHI KASEI CORPORATION: COMPANY SNAPSHOT (2022) 114
10.1.2 BEIJING STRONG BIOTECHNOLOGIES, INC. 116
TABLE 66 BEIJING STRONG BIOTECHNOLOGIES, INC.: BUSINESS OVERVIEW 116
FIGURE 33 BEIJING STRONG BIOTECHNOLOGIES, INC.: COMPANY SNAPSHOT (2022) 116
10.1.3 DIAZYME LABORATORIES, INC. 118
TABLE 67 DIAZYME LABORATORIES, INC.: COMPANY OVERVIEW 118
10.1.4 DXGEN CORP. 118
TABLE 68 DXGEN CORP: COMPANY OVERVIEW 118
10.1.5 WELDON BIOTECH, INC. 119
TABLE 69 WELDON BIOTECH, INC.: COMPANY OVERVIEW 119
10.1.6 HZYMES BIOTECH 119
TABLE 70 HZYMES BIOTECH: COMPANY OVERVIEW 119
*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
11 APPENDIX 120
11.1 DISCUSSION GUIDE 120
11.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 123
11.3 CUSTOMIZATION OPTIONS 125
11.4 RELATED REPORTS 125
11.5 AUTHOR DETAILS 126